Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Acquisitions & Divestments (2021 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Change in Acquisitions & Divestments for 5 consecutive years, with $32.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 49.24% to $32.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $367.0 million, a 178.59% increase, with the full-year FY2024 number at $169.0 million, down 2.48% from a year prior.
  • Change in Acquisitions & Divestments was $32.9 million for Q3 2025 at 4D Molecular Therapeutics, down from $101.6 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $205.3 million in Q3 2022 to a low of -$135.2 million in Q4 2022.
  • A 5-year average of $49.8 million and a median of $44.2 million in 2023 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: plummeted 2803.88% in 2022, then surged 1027.88% in 2025.
  • 4D Molecular Therapeutics' Change in Acquisitions & Divestments stood at $5.0 million in 2021, then tumbled by 2803.88% to -$135.2 million in 2022, then skyrocketed by 121.09% to $28.5 million in 2023, then surged by 130.72% to $65.8 million in 2024, then crashed by 49.95% to $32.9 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Change in Acquisitions & Divestments are $32.9 million (Q3 2025), $101.6 million (Q2 2025), and $166.7 million (Q1 2025).